Evidence map›Paper›PMID 38535445›Full record

ArticleMarine drugs2024

Cloning and Characterization of a Novel

Monica Daugbjerg Christensen, Leila Allahgholi, Javier A Linares-Pastén, Ólafur Friðjónsson, Hörður Guðmundsson, Varsha Kale, Roya R R Sardari, Guðmundur Ó Hreggviðsson, Eva Nordberg Karlsson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Marine drugs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Monica Daugbjerg ChristensenMatís, Vínlandsleið 12, 113 Reykjavik, Iceland.ORCID 0000-0002-5151-9932
Leila AllahgholiDivision of Biotechnology, Department of Chemistry, Lund University, P.O. Box 124, 22100 Lund, Sweden.
Javier A Linares-PasténDivision of Biotechnology, Department of Chemistry, Lund University, P.O. Box 124, 22100 Lund, Sweden.ORCID 0000-0001-6999-6334
Ólafur FriðjónssonMatís, Vínlandsleið 12, 113 Reykjavik, Iceland.
Hörður GuðmundssonMatís, Vínlandsleið 12, 113 Reykjavik, Iceland.ORCID 0000-0003-0731-3141
Varsha KaleMatís, Vínlandsleið 12, 113 Reykjavik, Iceland.
Roya R R SardariDivision of Biotechnology, Department of Chemistry, Lund University, P.O. Box 124, 22100 Lund, Sweden.ORCID 0000-0003-1462-8686
Guðmundur Ó HreggviðssonMatís, Vínlandsleið 12, 113 Reykjavik, Iceland.
Eva Nordberg KarlssonDivision of Biotechnology, Department of Chemistry, Lund University, P.O. Box 124, 22100 Lund, Sweden.ORCID 0000-0002-8597-7050
Lund University · SEMatís (Iceland) · ISUniversity of Iceland · IS

Funding

European Union's Horizon Europe program SeaMark (Seaweed based market applications) project 101060379
6 · The paper itself

Abstract

Sulfation is gaining increased interest due to the role of sulfate in the bioactivity of many polysaccharides of marine origin. Hence, sulfatases, enzymes that control the degree of sulfation, are being more extensively researched. In this work, a novel sulfatase (SulA1) encoded by the gene

Indexed as

ArthrobacterSulfatesAcetylgalactosamineChondroitin LyasesCloning, MolecularEscherichia coliGalactosamineSulfatasesAcetylgalactosamineChondroitin LyasesGalactosamineSulfatasesSulfateschondroitin sulfatemarine bacteriumN-acetylgalactosamine-4-O-sulfatesulfatase

Identifiers

PMID38535445
PMCPMC10972148
OpenAlexW4392097238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.